<qa>  What is the general aim of this study?The general aim of this study is to investigate the efficacy and safety of afatinib alone and in combination with weekly vinorelbine in patients who progress on afatinib monotherapy within this trial as treatment in patients with HER2-overexpressing, locally advanced or metastatic inflammatory breast cancer. The study will include patients who have and have not failed prior trastuzumab treatment. 